
Janine Diehl-Schmid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6101882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	7.6	3,913
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
3	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
4	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	2.6	171
5	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	7.6	158
6	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
7	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
8	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
9	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
10	Frontotemporal lobar degeneration: current perspectives. Neuropsychiatric Disease and Treatment, 2014, 10, 297.	2.2	95
11	The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia. Archives of Clinical Neuropsychology, 2007, 22, 459-464.	0.5	94
12	Polyâ€ <scp>GP</scp> in cerebrospinal fluid links <i>C9orf72</i> â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp> / <scp>FTD</scp> . EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
13	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
14	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
15	A 6â€month, openâ€label study of memantine in patients with frontotemporal dementia. International Journal of Geriatric Psychiatry, 2008, 23, 754-759.	2.7	87
16	The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease. Neurology, 2015, 84, 1956-1963.	1.1	87
17	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
18	Opposite microglial activation stages upon loss of <scp>PGRN</scp> or <scp>TREM</scp> 2 result in reduced cerebral glucose metabolism. EMBO Molecular Medicine, 2019, 11, .	6.9	87

#	Article	IF	CITATIONS
19	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
20	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
21	Caregiver Burden and Needs in Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 221-229.	2.3	80
22	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.1	73
23	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	2.5	68
24	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	2.7	64
25	Altered neurovascular coupling as measured by optical imaging: a biomarker for Alzheimer's disease. Scientific Reports, 2017, 7, 12906.	3.3	56
26	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
27	An augmented reality approach for ADL support in Alzheimer's disease: a crossover trial. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 66.	4.6	52
28	Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study. Journal of Nuclear Medicine, 2016, 57, 410-415.	5.0	50
29	Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. PLoS ONE, 2013, 8, e82879.	2.5	50
30	Guilty by Suspicion? Criminal Behavior in Frontotemporal Lobar Degeneration. Cognitive and Behavioral Neurology, 2013, 26, 73-77.	0.9	49
31	Metabolic connectivity for differential diagnosis of dementing disorders. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 252-262.	4.3	47
32	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
33	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	2.7	42
34	Long-term follow-up in primary progressive aphasia: Clinical course and health care utilisation. Aphasiology, 2014, 28, 981-992.	2.2	41
35	Imaging Frontotemporal Lobar Degeneration. Current Neurology and Neuroscience Reports, 2014, 14, 489.	4.2	41
36	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40

#	Article	IF	CITATIONS
37	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
38	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
39	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO Journal, 2022, 41, e109108.	7.8	38
40	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
41	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	3.4	34
42	The Role of Coping Strategies in Psychological Outcomes for Frontotemporal Dementia Caregivers. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 218-228.	2.3	33
43	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
44	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	4.8	28
45	Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET. PLoS ONE, 2013, 8, e55415.	2.5	25
46	RHAPSODY – Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study. International Psychogeriatrics, 2016, 28, 2091-2099.	1.0	24
47	The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study. Scientific Reports, 2022, 12, 2418.	3.3	24
48	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
49	Integrity of Neurocognitive Networks in Dementing Disorders as Measured with Simultaneous PET/Functional MRI. Journal of Nuclear Medicine, 2020, 61, 1341-1347.	5.0	23
50	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
51	Trends of patient referral to a memory clinic and towards earlier diagnosis from 1985–2009. International Psychogeriatrics, 2015, 27, 1939-1944.	1.0	22
52	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
53	Facial Emotion Recognition Performance Differentiates Between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. Journal of Clinical Psychiatry, 2018, 79, 16m11342.	2.2	22
54	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	1.9	21

#	Article	IF	CITATIONS
55	A multivariate metabolic imaging marker for behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 583-594.	2.4	20
56	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
57	Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer's Disease. Biological Psychiatry, 2015, 77, 704-710.	1.3	17
58	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17
59	Progressively Disrupted Intrinsic Functional Connectivity of Basolateral Amygdala in Very Early Alzheimer's Disease. Frontiers in Neurology, 2016, 7, 132.	2.4	16
60	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
61	The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimer's Research and Therapy, 2022, 14, 60.	6.2	16
62	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
63	Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease. BMC Neurology, 2019, 19, 264.	1.8	15
64	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
65	Perceived Need and Acceptability of an App to Support Activities of Daily Living in People With Cognitive Impairment and Their Carers: Pilot Survey Study. JMIR MHealth and UHealth, 2020, 8, e16928.	3.7	14
66	18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases. Molecular Psychiatry, 2020, 25, 2608-2619.	7.9	13
67	Dissociation in Rating Negative Facial Emotions between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 1017-1027.	1.2	11
68	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. Journal of Alzheimer's Disease, 2021, 84, 1153-1161.	2.6	11
69	Mapping covariance in brain FDG uptake to structural connectivity. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1288-1297.	6.4	11
70	Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. Neurolmage: Clinical, 2020, 25, 102112.	2.7	10
71	Culture in the spotlight—cultural adaptation and content validity of the integrated palliative care outcome scale for dementia: A cognitive interview study. Palliative Medicine, 2021, 35, 962-971.	3.1	10
72	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10

#	Article	IF	CITATIONS
73	Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers. Alzheimer's Research and Therapy, 2022, 14, 61.	6.2	9
74	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
75	Health Care Utilization in Frontotemporal Lobar Degeneration. Alzheimer Disease and Associated Disorders, 2012, 26, 166-170.	1.3	7
76	IssuEs in Palliative care for people in advanced and terminal stages of Young-onset and Late-Onset dementia in GErmany (EPYLOGE): the study protocol. BMC Psychiatry, 2018, 18, 271.	2.6	7
77	Step by Step: Kinematics of the Reciprocal Trail Making Task Predict Slowness of Activities of Daily Living Performance in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 140.	2.4	7
78	Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease. Neurodegenerative Diseases, 2019, 19, 43-50.	1.4	7
79	<p>Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil</p> . Drug Design, Development and Therapy, 2020, Volume 14, 3251-3262.	4.3	7
80	Regional Cerebral Associations Between Psychometric Tests and Imaging Biomarkers in Alzheimer's Disease. Frontiers in Psychiatry, 2020, 11, 793.	2.6	7
81	Quality of Life in Advanced Dementia with Late Onset, Young Onset, and Very Young Onset. Journal of Alzheimer's Disease, 2021, 80, 283-297.	2.6	7
82	Clonal hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders. Human Molecular Genetics, 2022, 31, 2386-2395.	2.9	7
83	How Do Persons with Young and Late Onset Dementia Die?. Journal of Alzheimer's Disease, 2021, 81, 843-852.	2.6	6
84	Suicidal Ideations and Behavior in Patients With Young and Late Onset Dementia. Frontiers in Neurology, 2021, 12, 647396.	2.4	6
85	Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer's Dementia Are Frequently Below the Recommended Levels. Frontiers in Pharmacology, 2020, 11, 691.	3.5	5
86	A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia. BMC Geriatrics, 2022, 22, 214.	2.7	5
87	Cerebrospinal fluid biomarkers for Alzheimer's disease: the role of apolipoprotein E genotype, age, and sex. Neuropsychiatric Disease and Treatment, 2015, 11, 3105.	2.2	4
88	Modern technology to support carers of care recipients with dementia or functional mental illness: promising progress, but a long road ahead. International Psychogeriatrics, 2017, 29, 1933-1935.	1.0	4
89	An Explorative Note on Apraxia Tests. Frontiers in Neurology, 2018, 9, 660.	2.4	4
90	<p>Decreased Vascular Pulsatility in Alzheimer's Disease Dementia Measured by Transcranial Color-Coded Duplex Sonography</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3487-3499.	2.2	4

0

#	Article	IF	CITATIONS
91	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	2.4	4
92	>Dementia care in the Danube Region. A multi-national expert survey. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2503-2511.	2.2	3
93	The solely A+ CSF Aβ42/40 ratio using Elecsys ® assays performs similar to A/T and A/N ratios in predicting amyloid PET positivity. Alzheimer's and Dementia, 2020, 16, e046988.	0.8	2
94	Variability of clinical syndromes and cerebral glucose metabolism in symptomatic frontotemporal lobar degeneration associated with progranulin mutations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 389-395.	1.7	2
95	Development and testing of an informative guide about palliative care for family caregivers of people with advanced dementia. BMC Palliative Care, 2020, 19, 30.	1.8	2
96	Intrathecal antibodies against herpes simplex virus are associated with tau pathology in humans with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041938.	0.8	1
97	Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1–40: A Correlational Study in Healthy Adults. Journal of Alzheimer's Disease, 2021, 83, 155-162.	2.6	1
98	Anticipatory and Reactive Grip Force Control in Patients with Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease, 2021, 82, 1651-1665.	2.6	1
99	O3â€10â€05: Advanced Disease Stages and Death in Behavioral Variant Frontotemporal Dementia: A Step to Palliative Care. Alzheimer's and Dementia, 2016, 12, P311.	0.8	0
100	P2â€204: Phenotypic Variability in C9ORF72 Mutation Carriers from the German FTLDâ€Consortium. Alzheimer's and Dementia, 2016, 12, P699.	0.8	0
101	Quantitative mass spectrometry suggests betaâ€synuclein as promising blood marker for synaptic degeneration in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040246.	0.8	0
102	Altered cerebral vessel amplitude and oscillation frequencies in Alzheimer's disease compatible with impaired amyloid clearance. Alzheimer's and Dementia, 2020, 16, e044460.	0.8	0
103	Differences in sex distribution between genetic and sporadic FTD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
104	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
105	Neuronavigated repetitive transcranial magnetic stimulation as novel mapping technique provides insights into language function in primary progressive aphasia. Brain Imaging and Behavior, 2022, 16, 1208-1216.	2.1	0
106	Ageâ€dependency of total tau in the cerebrospinal fluid is corrected by amyloidâ€beta 1â€40: A correlational study in healthy adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
107	Title is missing!. , 2020, 17, e1003289.		0

